+44 20 8123 2220
info@marketpublishers.com

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

https://marketpublishers.com/r/H0FE232AB96EN.html
Date: May 2018
Pages: 67
Price: US$ 3,500.00 (Single User License)
ID: H0FE232AB96EN

Abstracts

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

SUMMARY

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 4 - Pipeline Review, H1 2018, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Histone deacetylase 4 (HDAC4) is a protein encoded by the HDAC4 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. It acts via the formation of large multiprotein complexes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Ophthalmology which include indications Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colon Cancer, Congestive

Heart Failure (Heart Failure), Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Essential Thrombocythemia, Follicular Lymphoma, Gallbladder Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leiomyosarcoma, Liver Cancer, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Myelodysplastic Syndrome, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Retinitis Pigmentosa (Retinitis) and Sezary Syndrome.

Furthermore, this report also reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

The report reviews Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects

The report assesses Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
AlfaSigma SpA
HitGen LTD
MEI Pharma Inc
Mirati Therapeutics Inc
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles
Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mocetinostat - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
pracinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resminostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jan 31, 2018: Positive DSMB safety review of 4SC's pivotal RESMAIN study of resminostat in CTCL
Jan 11, 2018: Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)
Dec 20, 2017: 4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
Dec 13, 2017: 4SC receives milestone payment from Immunic
Oct 12, 2017: Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative for NSCLC Patients
Oct 10, 2017: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
Sep 13, 2017: Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer
Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase

+44 20 8123 2220
info@marketpublishers.com

2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome
Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup
Jan 05, 2017: Mirati Therapeutics Provides Update On Mocetinostat Program
Dec 16, 2016: First patient enrolled in pivotal RESMAIN study of resminostat in CTCL
Dec 05, 2016: Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by 4SC AG, H1 2018
Pipeline by AlfaSigma SpA, H1 2018
Pipeline by HitGen LTD, H1 2018
Pipeline by MEI Pharma Inc, H1 2018
Pipeline by Mirati Therapeutics Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Discontinued Products, H1 2018

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

4SC AG
AlfaSigma SpA
HitGen LTD
MEI Pharma Inc
Mirati Therapeutics Inc

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline Review, H1 2018

Product link: https://marketpublishers.com/r/H0FE232AB96EN.html

Price: US$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H0FE232AB96EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com